Explore the words cloud of the THERACAN project. It provides you a very rough idea of what is the project "THERACAN" about.
The following table provides information about the project.
FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III
|Coordinator Country||Spain [ES]|
|Total cost||2˙499˙500 €|
|EC max contribution||2˙499˙500 € (100%)|
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
|Duration (year-month-day)||from 2017-01-01 to 2021-12-31|
Take a look of project's partnership.
|1||FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III||ES (MADRID)||coordinator||2˙499˙500.00|
This proposal is aimed at identifying and functionally validating targets with potential therapeutic value to devise novel strategies to treat two human cancers with unacceptable low survival rates and unmet medical needs: pancreatic ductal adenocarcinoma and K-RAS mutant lung adenocarcinoma. Although these tumor types have distinct pathological and clinical manifestations, they are both driven by K-RAS mutations. Hence, we expect that the proposed studies will generate synergies to accelerate the outcome of the expected results. In the first part of the proposal, we will identify those genes activated in the cancer initiating cells responsible for the onset of pancreatic and lung tumors. We reasoned that genes implicated in the initial stages of tumor development will be maintained during tumor evolution and not be affected by the intra-tumoral heterogeneity generated during tumor progression. We also propose to identify and validate genes capable of reprogramming the desmoplasic stroma characteristic of pancreatic tumors to hamper its pro-tumoral effects. Likewise, we intend to define the molecular events that control senescence, a naturally occurring process that serves as a barrier to tumor development. In the second part of the project, we will interrogate the role of known targets with suspected therapeutic value in tumor progression using a new generation of GEM tumor models that allow the temporal separation of tumor development from target ablation or inactivation. These studies will make it possible to design combination therapies capable of effectively eradicate advanced tumors. The last section of this proposal focuses on the pharmacological validation of these combination therapies using best-in-class inhibitors in state-of-the-art preclinical trial platforms based on GEM and PDX tumor models. The results derived from these studies will guide the design of new clinical trials that should have a positive impact in the treatment of these deadly diseases.
|year||authors and title||journal||last update|
Magdolna Djurec, Osvaldo GraÃ±a, Albert Lee, Kevin TroulÃ©, Elisa Espinet, Lavinia Cabras, Carolina Navas, MarÃa Teresa Blasco, Laura MartÃn-DÃaz, Miranda Burdiel, Jing Li, Zhaoqi Liu, Mireia VallespinÃ³s, Francisco Sanchez-Bueno, Martin R. Sprick, Andreas Trumpp, Bruno Sainz, FÃ¡tima Al-Shahrour, Raul Rabadan, Carmen Guerra, Mariano Barbacid
Saa3 is a key mediator of the protumorigenic properties of cancer-associated fibroblasts in pancreatic tumors
published pages: E1147-E1156, ISSN: 0027-8424, DOI: 10.1073/pnas.1717802115
|Proceedings of the National Academy of Sciences 115/6||2019-08-29|
LucÃa SimÃ³n-Carrasco, Gerardo JimÃ©nez, Mariano Barbacid, Matthias Drosten
The Capicua tumor suppressor: a gatekeeper of Ras signaling in development and cancer
published pages: 702-711, ISSN: 1538-4101, DOI: 10.1080/15384101.2018.1450029
|Cell Cycle 17/6||2019-08-29|
MarÃa Teresa Blasco, Carolina Navas, Guillermo MartÃn-Serrano, Osvaldo GraÃ±a-Castro, Carmen G. Lechuga, Laura MartÃn-DÃaz, Magdolna Djurec, Jing Li, Lucia Morales-Cacho, Laura Esteban-Burgos, Javier Perales-PatÃ³n, Emilie Bousquet-Mur, Eva Castellano, Harrys K.C. Jacob, Lavinia Cabras, Monica Musteanu, Matthias Drosten, Sagrario Ortega, Francisca Mulero, Bruno Sainz, Nelson Dusetti, Juan Iova
Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF
published pages: 573-587.e6, ISSN: 1535-6108, DOI: 10.1016/j.ccell.2019.03.002
|Cancer Cell 35/4||2019-08-29|
Matthias Drosten, Carmen Guerra, Mariano Barbacid
Genetically Engineered Mouse Models of K-Ras-Driven Lung and Pancreatic Tumors: Validation of Therapeutic Targets
published pages: a031542, ISSN: 2157-1422, DOI: 10.1101/cshperspect.a031542
|Cold Spring Harbor Perspectives in Medicine 8/5||2019-08-29|
Manuel Sanclemente, Sarah Francoz, Laura Esteban-Burgos, Emilie Bousquet-Mur, Magdolna Djurec, Pedro P. Lopez-Casas, Manuel Hidalgo, Carmen Guerra, Matthias Drosten, Monica Musteanu, Mariano Barbacid
c-RAF Ablation Induces Regression of Advanced Kras/Trp 53 Mutant Lung Adenocarcinomas by a Mechanism Independent of MAPK Signaling
published pages: 217-228.e4, ISSN: 1535-6108, DOI: 10.1016/j.ccell.2017.12.014
|Cancer Cell 33/2||2019-06-13|
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "THERACAN" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "THERACAN" are provided by the European Opendata Portal: CORDIS opendata.